Biologics Fill Finish Services Market: Industry Trends and Global Forecasts to 2035

The global biologics fill finish manufacturing market is estimated to grow from USD 5.3 billion in the current year to USD 11.6 billion by 2035, at a CAGR of 7.4% during the forecast period, until 2035.

Biologics Fill Finish Services Market: Growth and Trends

Biopharmaceuticals, commonly referred to as biologics, are a class of therapeutic products that are either derived from living organisms or semi-synthesized from biological sources. Unlike traditional small molecules, these macromolecules are complex and are developed to target specific protein receptors in the body. It is worth mentioning that, over the years, these therapies have gained immense popularity owing to their favorable therapeutic outcomes demonstrated across various therapeutic areas, such as oncological disorders, infectious diseases and neurovascular disorders.

Furthermore, the evolution of drug development process has led to technical advancements that have further streamlined the entire process of manufacturing these complex biologics. However, it is worth noting that the biopharmaceutical industry has dealt with several challenges, in terms of inadequate capital investments, sterility issues, and stringent quality standards imposed by different regulatory authorities globally. As a result, outsourcing of manufacturing and fill / finish operations for biologics has emerged as a suitable option to meet the evolving demand of the industry.

Driven by the growing demand for biologics and technological advancements (such as use of automation and robotics) in fill finish operations, the biologics fill finish manufacturing market is anticipated to witness substantial market growth, during the forecast period.

Biologics Fill Finish Services Market: Key Insights

The report delves into the current state of the biologics fill finish services market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

Presently, 240+ service providers are engaged in offering fill / finish services for various biologic molecules; close to 35% of these companies are headquartered in the US.

80% of the service providers operate at all scales of operation to cater to the diverse fill / finish requirements of their clients; notably, vials have emerged as the most adopted primary packaging container format.
In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities and enhancing their respective service offerings to comply with the evolving industry benchmarks.
Over the past few years, the field has witnessed a notable increase in expansion and partnership activity for biologics fill / finish capabilities.
The global, installed biologics fill / finish capacity is spread across various geographies; interestingly, more than 90% of the total capacity is installed at the facilities owned by large and very large players.
Given the growing pipeline of biologic drug products, the demand for fill-finish services has upsurged; by 2035, it is anticipated to reach over 28.5 million liters, across clinical and commercial scales of operation.
With the rapid increase in the demand for biologics for the treatment of chronic conditions, the BFF market is poised to grow at a CAGR of 7.4%, till 2035; the market in Asia-Pacific is likely to grow at a faster pace.

Close to 30% of the market is expected to be captured by revenues generated from fill / finish services of biologics for oncological disorders; vials are expected to capture majority share (over 65%) of the market by 2035.

Biologics Fill Finish Services Market: Key Segments

Currently, Vials Occupy the Largest Share of the Biologics Fill Finish Services Market

Based on the type of primary packaging container, the market is segmented into ampoules, cartridges, syringes and vials. At present, the vials segment holds the maximum share of the biologics fill finish services market and this trend is likely to remain the same in the short-mid term. Vials offer various benefits, such as the ability to pre-sterilize the containers using various terminal sterilization techniques, ease of filling and minimal risk of breakage during handling, and transportation. It is worth highlighting that syringes segment is likely to grow at a relatively higher CAGR during the forecast period.

Antibodies Segment is Likely to Dominate the Biologics Fill Finish Services Market During the Forecast Period

Based on the type of biologic manufactured, the market is segmented into antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines and other biologics. Given that monoclonal antibodies have high specificity and low toxicity, these molecules are widely adopted for various applications leading to the highest share in the biologics fill finish manufacturing market. This trend is unlikely to change in the near future.

Currently, Commercial Scale Occupies the Largest Share of the Biologics Fill Finish Services Market

Based on the scale of operation, the market is segmented into preclinical / clinical and commercial scale. At present, the commercial scale holds the maximum share of the biologics fill finish services market. This trend is likely to remain the same in the forthcoming years.

Oncological Disorders Segment Accounts for the Largest Share of the Biologics Fill Finish Services Market

Based on the therapeutic area, the market is segmented into autoimmune disorders, cardiovascular disorders, infectious diseases, metabolic disorders, oncological disorders and other disorders. While oncological disorders account for a relatively higher market share, it is worth highlighting that autoimmune disorders segment is expected to witness substantial market growth in the coming years.

Small Companies Offering Biologics Fill Finish Services are the Fastest Growing Segment of the Biologics Fill Finish Services Market During the Forecast Period

Based on the company size, the market is segmented into small companies, mid-sized companies, and large companies. It is worth highlighting that, at present, large companies hold a larger share in the biologics fill finish services market. This trend is likely to remain the same in the coming decade.

Pharmaceutical / Biopharmaceutical Companies are Likely to Dominate the Biologics Fill Finish Services Market During the Forecast Period

Based on the end-users, the market is segmented into pharmaceutical / biopharmaceutical companies and contract manufacturing organizations / others. It is worth highlighting that the majority of the current biologics fill finish services market is captured by pharmaceutical / biopharmaceutical companies. This trend is likely to remain the same in the coming decade.

Industry Players are Likely to Dominate the Biologics Fill Finish Services Market During the Forecast Period

Based on the type of player, the market is segmented into industry players and non-industry players. It is worth highlighting that majority of the current biologics fill finish services market is captured by industry players. This trend is likely to remain the same in the coming decade.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority share is expected to be captured by drug developers based in Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Biologics Fill Finish Manufacturing Market Profiled in the Report:

AbbVie Contract Manufacturing
Asymchem
Boehringer Ingelheim BioXcellence
Catalent Biologics
Charles River
Evonik
Fareva
Fresenius Kabi
GSK
Hetero
Lonza
Patheon Pharma Services
Pierre Fabre
Recipharm
Sandoz
Syngene
WACKER
WuXi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Former Chief Commercial Officer, IDT Biologika
Vice President of Business Development, Alcami
Vice President, Syngene
Former-Vice President of Business Development and Marketing, Cytovance Biologics
Head of Business Development, oncomed manufacturing
Business Development Manager, Eurofins BioPharma Product Testing Netherlands
Former -Technology Watch Manager, Yposkesi
Former Global Business Development Manager, HALIX
Business Development Specialist, Mabion

Biologics Fill Finish Manufacturing Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biologics fill finish manufacturing market, focusing on key market segments, including [A] type of primary packaging container, [B] type of biologic manufactured, [C] scale of operation, [D] therapeutic area, [E] end-users, [F] type of player, [G] company size and [H] key geographical regions.
Market Landscape: A comprehensive evaluation of companies involved in the biologics fill finish manufacturing market, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] location of fill finish facilities, [E] scale of operation, [F] type of biologic manufactured, [G] type of dosage form, [H] type of primary packaging container used and [I] additional services offered.
Company Profiles: In-depth profiles of key industry players offering biologics fill finish services, focusing on [A] company overviews, [B] financial information (if available), [C] fill / finish service portfolio, [D] recent developments and [E] an informed future outlook.
Company Competitiveness Analysis: A comprehensive competitive analysis of biologics fill finish manufacturing service providers, examining factors such as [A] supplier strength, [B] portfolio strength and [C] service strength.
Partnerships and Collaborations: An analysis of partnerships established in this sector, based on several parameters, such as [A] year of partnership, [B] type of partnership (including service agreement, service alliance, product integration agreement and joint venture and acquisition), [C] scale of operation, [D] type of service offered, [E] type of process involved, [F] type of biologic involved, [G] location of headquarters or location of facility and [H] most active players (in terms of number of partnerships).
Recent Expansion Initiatives: An examination of the different expansion efforts made by contract manufacturing organizations to enhance biologics fill finish capabilities. This analysis considers various factors, including the [A] year of expansion, [B] type of expansion, [C] type of primary packaging container used, [D] type of service offered, [E] type of biologic involved, [F] scale of operation, [G] most active players (in terms of number of expansion initiatives) and [H] expansion details.
Capacity Analysis: Estimation of global biologics fill finish capacity, derived from data provided by various industry stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size (small, mid-sized, and large and very large firms) and [B] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
Demand Analysis: Informed estimates of the annual demand for biologics fill-finish manufacturing based on several relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength of the aforementioned products.
Key Performance Indicators: An analysis highlighting the key performance indicators to evaluate service providers engaged in the biologics fill finish domain, based on information gathered via secondary research (for top-ten biopharmaceutical players) and primary research.
Capability Assessment: A comprehensive regional capability assessment framework that evaluates key geographies by various parameters, including [A] number of biologics fill finish service providers, [B] number of biologics fill finish facilities, [C] scale of operation, [D] installed biologic fill/finish capacity and [E] annual demand in that particular geographical region.
Case Study 1: A case study focused on use of robotic systems in fill/finish operations. It provides a list of equipment used by the service providers (wherever specified) for fill finish operations, highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies providing robots for use in manufacturing processes carried in the pharmaceutical industry.
Case Study 2: A case study on the use of ready to use packaging components in the aseptic fill finish operations. It also provides a list of suppliers providing ready-to-use components.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What is the current annual demand for biologics?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage and Foreign Exchange Rates
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2.Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

4.1. Chapter Overview

5. INTRODUCTION

5.1. Chapter Overview
5.2. Introduction to Biologics
5.3.Need for Outsourcing Biologics-related Operations
5.4. Role of Contract Manufacturers in the Biopharmaceutical Industry
5.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
5.5.1. Biologics Fill / Finish Operations
5.6.Key Considerations while Selecting a Fill / Finish Service Provider
5.7.Advantages of Outsourcing Fill / Finish Operations
5.8. Risks and Challenges of Outsourcing Fill / Finish Operations
5.9. Conclusion

6. MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Fill / Finish Facilities
6.2.5. Analysis by Scale of Operation
6.2.6. Analysis by Type of Biologic Manufactured
6.2.7. Analysis by Type of Dosage Form
6.2.8. Analysis by Type of Primary Packaging Container Used
6.2.9. Analysis by Additional Services Offered

7. COMPANY PROFILES

7.1. Chapter Overview
7.2. Detailed Company Profiles of Biologics Fill / Finish Service Providers
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Overview
7.2.1.2. Financial Information
7.2.1.3. Biologics Fill / Finish Service Portfolio
7.2.1.4. Recent Developments and Future Outlook
7.2.2. Asymchem
7.2.2.1. Company Overview
7.2.2.2. Financial Information
7.2.2.3. Biologics Fill / Finish Service Portfolio
7.2.2.4. Recent Developments and Future Outlook
7.2.3. Boehringer Ingelheim BioXcellence
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Biologics Fill / Finish Service Portfolio
7.2.3.4. Recent Developments and Future Outlook
7.2.4. Catalent Biologics
7.2.4.1. Company Overview
7.2.4.2. Financial Information
7.2.4.3. Biologics Fill / Finish Service Portfolio
7.2.4.4. Recent Developments and Future Outlook
7.2.5. Fresenius Kabi
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Biologics Fill / Finish Service Portfolio
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Lonza
7.2.6.1. Company Overview
7.2.6.2. Financial Information
7.2.6.3. Biologics Fill / Finish Service Portfolio
7.2.6.4. Recent Developments and Future Outlook
7.2.7. Patheon pharma services
7.2.7.1. Company Overview
7.2.7.2. Financial Information
7.2.7.3. Biologics Fill / Finish Service Portfolio
7.2.7.4. Recent Developments and Future Outlook
7.2.8. Recipharm
7.2.8.1. Company Overview
7.2.8.2. Financial Information
7.2.8.3. Biologics Fill / Finish Service Portfolio
7.2.8.4. Recent Developments and Future Outlook
7.2.9. WACKER
7.2.9.1. Company Overview
7.2.9.2. Financial Information
7.2.9.3. Biologics Fill / Finish Service Portfolio
7.2.9.4. Recent Developments and Future Outlook
7.2.10. WuXi Biologics
7.2.10.1. Company Overview
7.2.10.2. Financial Information
7.2.10.3. Biologics Fill / Finish Service Portfolio
7.2.10.4. Recent Developments and Future Outlook
7.3. Short Company Profiles of Other Prominent Biologics Fill / Finish Service Providers
7.3.1. Charles River
7.3.1.1. Company Overview
7.3.1.2. Biologics Fill / Finish Service Portfolio
7.3.2. Elements Material Technology
7.3.2.1. Company Overview
7.3.2.2. Biologics Fill / Finish Service Portfolio
7.3.3. Evonik
7.3.3.1. Company Overview
7.3.3.2. Biologics Fill / Finish Service Portfolio
7.3.4. Fareva
7.3.4.1. Company Overview
7.3.4.2. Biologics Fill / Finish Service Portfolio
7.3.5. GSK 7.3.5.1. Company Overview
7.3.5.2. Biologics Fill / Finish Service Portfolio
7.3.6. Hetero
7.3.6.1. Company Overview
7.3.6.2. Biologics Fill / Finish Service Portfolio
7.3.7. Pierre Fabre
7.3.7.1. Company Overview
7.3.7.2. Biologics Fill / Finish Service Portfolio
7.3.8. Sandoz
7.3.8.1. Company Overview
7.3.8.2. Biologics Fill / Finish Service Portfolio
7.3.9. Syngene
7.3.9.1. Company Overview
7.3.9.2. Biologics Fill / Finish Service Portfolio

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview 8.2. Methodology and Key Parameters
8.3. Biologics Fill / Finish Service Providers Based in North America
8.3.1. Companies Offering Fill / Finish Services for Ampoules
8.3.2. Companies Offering Fill / Finish Services for Cartridges
8.3.3. Companies Offering Fill / Finish Services for Syringes
8.3.4. Companies Offering Fill / Finish Services for Vials
8.4. Biologics Fill / Finish Service Providers Based in Europe
8.4.1. Companies Offering Fill / Finish Services for Ampoules
8.4.2. Companies Offering Fill / Finish Services for Cartridges
8.4.3. Companies Offering Fill / Finish Services for Syringes
8.4.4. Companies Offering Fill / Finish Services for Vials
8.5. Biologics Fill / Finish Service Providers Based in Asia-Pacific and Rest of the World
8.5.1. Companies Offering Fill / Finish Services for Ampoules
8.5.2. Companies Offering Fill / Finish Services for Cartridges
8.5.3. Companies Offering Fill / Finish Services for Syringes
8.5.4. Companies Offering Fill / Finish Services for Vials

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Biologics Fill / Finish Service Providers: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Service Offered
9.3.5. Analysis by Type of Process Involved
9.3.6. Analysis by Type of Biologic Involved
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Analysis by Geography
9.3.8.1. International and Local Agreements
9.3.8.2. Intercontinental and Intracontinental Agreements

10. RECENT EXPANSIONS

10.1. Chapter Overview
10.2. Biologics Fill / Finish Service Providers: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Packaging Container Used
10.2.4. Analysis by Type of Service Offered
10.2.5. Analysis by Type of Biologic Involved
10.2.6. Analysis by Type of Biologic Involved and Scale of Operation
10.2.7. Most Active Players: Analysis by Number of Expansions
10.2.8. Analysis by Geography
10.2.8.1. Expansions Undertaken in North America: Analysis by Type of Service Offered and Type of Biologic Involved
10.2.8.2. Expansions Undertaken in Europe: Analysis by Type of Service Offered and Type of Biologic Involved
10.2.8.3. Expansions Undertaken in Asia-Pacific and Rest of the World: Analysis by Type of Service Offered and Type of Biologic Involved

11. CAPACITY ANALYSIS

11.1. Chapter Overview
11.2. Global Installed Biologics Fill / Finish Capacity for Ampoules (Number of Units)
11.2.1. Key Assumptions and Methodology
11.2.2. Analysis by Company Size
11.2.3. Analysis by Geography
11.2.3.1. Analysis of Biologics Fill / Finish Capacity for Ampoules in North America
11.2.3.2. Analysis of Biologics Fill / Finish Capacity for Ampoules in Europe
11.2.3.3. Analysis of Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
11.3. Global Installed Biologics Fill / Finish Capacity for Cartridges (Number of Units)
11.3.1 Key Assumptions and Methodology
11.3.2. Analysis by Company Size
11.3.3. Analysis by Geography
11.3.3.1. Analysis of Biologics Fill / Finish Capacity for Cartridges in North America
11.3.3.2. Analysis of Biologics Fill / Finish Capacity for Cartridges in Europe
11.3.3.3. Analysis of Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
11.4. Global Installed Biologics Fill / Finish Capacity for Syringes (Number of Units)
11.4.1. Key Assumptions and Methodology
11.4.2. Analysis by Company Size
11.4.3. Analysis by Geography 11.4.3.1. Analysis of Biologics Fill / Finish Capacity for Syringes in North America
11.4.3.2. Analysis of Biologics Fill / Finish Capacity for Syringes in Europe
11.4.3.3. Analysis of Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
11.4.3.4. Analysis of Biologics Fill / Finish Capacity for Syringes in Rest of the World
11.5. Global Installed Biologics Fill / Finish Capacity for Vials (Number of Units)
11.5.1. Key Assumptions and Methodology
11.5.2. Analysis by Company Size
11.5.3. Analysis by Geography
11.5.3.1. Analysis of Biologics Fill / Finish Capacity for Vials in North America
11.5.3.2. Analysis of Biologics Fill / Finish Capacity for Vials in Europe
11.5.3.3. Analysis of Biologics Fill / Finish Capacity for Vials in Asia-Pacific
11.5.3.4. Analysis of Biologics Fill / Finish Capacity for Vials in Rest of the World
11.6. Concluding Remarks

12. DEMAND ANALYSIS

12.1 Chapter Overview
12.2. Assumptions and Methodology
12.3. Global Annual Demand for Biologics Fill / Finish Manufacturing
12.3.1. Analysis by Scale of Operation
12.3.2. Analysis by Type of Primary Packaging Container Used
12.3.3. Analysis by Geography

13. KEY PERFORMANCE INDICATORS FOR BIOLOGIC MANUFACTURING AND FILL / FINISH

13.1. Chapter Overview
13.2. Biologics Manufacturing and Fill / Finish: Key Performance Indicators
13.2.1. Financial Indicators
13.2.1.1. Big Pharma Perspective
13.2.1.2. Contract Manufacturers Perspective
13.2.2. Process and Capability Indicators
13.2.2.1. Big Pharma Perspective
13.2.2.2. Contract Manufacturers Perspective
13.2.3. Market Reputation Indicators
13.2.3.1. Big Pharma Perspective
13.2.3.2. Contract Manufacturers Perspective
13.2.4. Other Important Performance Indicators
13.3.5. Conclusion

14. REGIONAL CAPABILITY ANALYSIS

14.1. Chapter Overview
14.2. Key Assumptions and Parameters
14.3. Biologics Fill / Finish Manufacturing Capabilities in North America
14.4. Biologics Fill / Finish Manufacturing Capabilities in Europe
14.5. Biologics Fill / Finish Manufacturing Capabilities in Asia-Pacific and Rest of the World

15. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACAKGING

15.1. Chapter Overview
15.2. Role of Robotic Systems in Pharmaceutical Industry
15.3. Biologics Fill / Finish Service Providers: List of Equipment Offered
15.4 Role of Robotic Systems in Fill / Finish Operation
15.4.1. Types of Robots Used in Pharmaceutical Operations
15.4.2. Key Considerations for Selecting a Robotic System
15.4.3. Advantages of Robotic Systems in Fill / Finish Operations
15.4.4. Disadvantages of Robotic Systems in Fill / Finish Operations
15.5. Companies Providing Robots to be Used in the Pharmaceutical Industry
15.6. Companies Providing Isolator based Aseptic Filling Systems
15.7. Concluding Remarks

16. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH

16.1. Chapter Overview
16.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
16.2.1. Advantages of Ready-to-Use Packaging Components
16.2.2. Disadvantages of Ready-to-Use Packaging Components
16.3. Companies Providing Ready-to-Use Packaging Components 16.4. Concluding Remarks

17. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

17.1. Chapter Overview
17.2. Market Drivers
17.3. Market Restraints
17.4. Market Opportunities
17.5.Market Challenges
17.6. Conclusion

18. GLOBAL BIOLOGICS FILL / FINISH MANUFACTURING MARKET

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Global Biologics Fill / Finish Manufacturing Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
18.3.1. Scenario Analysis
18.3.1.1. Conservative Scenario
18.3.1.2. Optimistic Scenario
18.4. Key Market Segmentations

19. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PRIMARY PACKAGING CONTAINER

19.1. Chapter Overview 19.2. Key Assumptions and Methodology
19.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2018, 2024 and 2035
19.3.1. Vials: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.3.2. Syringes: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.3.3. Ampoules: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.3.4. Cartridges: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation

20. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2024 and 2035
20.3.1. Antibodies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.2. Vaccines: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.3. Recombinant Proteins: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.4. Cell Therapies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.5. Gene Therapies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.6. Oligonucleotides: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.7. Other Biologics: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation

21. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY SCALE OF OPERATION

21.1. Chapter Overview 21.2. Key Assumptions and Methodology
21.3. Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2018, 2024 and 2035
21.3.1. Commercial Scale: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.2. Preclinical / Clinical Scale: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation

22. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY THERAPEUTIC AREA

22.1. Chapter Overview 22.2. Key Assumptions and Methodology
22.3. Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
22.3.1. Oncological Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2. Cardiovascular Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3. Metabolic Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.4. Infectious Diseases: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.5. Autoimmune Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.11. Other Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation

23. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY END-USERS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Biologics Fill / Finish Manufacturing Market: Distribution by End-users, 2018, 2024 and 2035
23.3.1. Pharmaceutical / Biopharmaceutical Companies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.3.2. Contract Manufacturing Organizations / Others: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation

24. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PLAYER

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player, 2018, 2024 and 2035
24.3.1. Industry Players: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
24.3.2. Non-Industry Players: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation

25. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY COMPANY SIZE

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biologics Fill / Finish Manufacturing Market: Distribution by Company Size, 2018, 2024 and 2035
25.3.1. Large Companies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
25.3.2. Mid-sized Companies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
25.3.3. Small Companies: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation

26. BIOLOGICS FILL / FINISH MANUFACTURING MARKET: BY KEY GEOGRAPHICAL REGIONS

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Biologics Fill / Finish Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
26.3.1. North America: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.1.1. US: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.1.2. Canada: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.1.3. Mexico: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2. Europe: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.1. France: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.2. Germany: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.3. UK: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.4. Italy: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.5. Spain: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.6. Austria: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.7. Switzerland: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2.8. Rest of Europe: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3. Asia-Pacific: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3.1. China: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3.2. India: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3.3. South Korea: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3.4. Japan: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3.5. Rest of Asia-Pacific: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.4. Rest of the World: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.4.1. Argentina: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.4.2. Brazil: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.4.3. Israel: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.4.4. Iran: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.4.5. Other Countries: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation

27. EXECUTIVE INSIGHTS

27.1. Chapter Overview
27.2. IDT Biologika
27.2.1. Company Snapshot
27.2.1. Interview Transcript: Gregor Kawaletz, Former-Chief Commercial Officer
27.3 Alcami
27.3.1. Company Snapshot
27.3.2. Interview Transcript: Chris Olson, Vice President of Business Development
27.4 Cytovance Biologics
27.4.1. Company Snapshot
27.4.2. Interview Transcript: Matt Delaney, Former-Vice President of Business Development and Marketing
27.5. Syngene
27.5.1. Company Snapshot
27.5.2. Interview Transcript: Purushottam Singnurkar, Vice
27.6 oncomed manufacturing
27.6.1. Company Snapshot
27.6.2. Interview Transcript: Ales Sima, Head of Business Development
27.7 Eurofins BioPharma Product Testing Netherlands
27.7.1. Company Snapshot
27.7.2. Interview Transcript: Valentinos Mouarrawis, Business Development Manager
27.8 Yposkesi
27.7.1. Company Snapshot
27.7.2. Interview Transcript: Amit, Former -Technology Watch Manager
27.9 HALIX 27.9.1. Company Snapshot
27.9.2. Interview Transcript: Jos Vergeest, Former Global Business Development Manager
27.10 Mabion
27.10.1. Company Snapshot
27.10.2. Interview Transcript: Jakub Knurek, Business Developement Specialist

28. CONCLUDING REMARKS

28.1. Chapter Overview

29. APPENDIX I: TABULATED DATA30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Recent Expansions
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Demand Analysis
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Types of Biologics
Figure 5.2 Commonly Outsourced Operations in Biopharmaceutical Industry
Figure 5.3 Steps Involved in Fill / Finish of Biologics
Figure 5.4 Key Considerations while Selecting a Fill / Finish Service Provider
Figure 5.5 Advantages of Outsourcing Biologics Fill / Finish Operations
Figure 6.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 6.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Figure 6.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 6.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 6.5 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 6.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Manufactured
Figure 6.7 Biologics Fill / Finish Service Providers: Distribution by Type of Dosage Form
Figure 6.8 Biologics Fill / Finish Service Providers: Distribution by Type of Primary Packaging Container Used
Figure 6.9 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
Figure 7.1 AbbVie (Parent Company of AbbVie Contract Manufacturing): Annual Revenues, FY 2019 Onwards (USD Billion)
Figure 7.2 Asymchem: Annual Revenues, FY 2019 Onwards (RMB Billion)
Figure 7.3 Boehringer Ingelheim (Parent Company of Boehringer Ingelheim BioXcellence): Annual Revenues, FY 2019 Onwards (EUR Billion)
Figure 7.4 Catalent (Parent Company of Catalent Biologics): Annual Revenues, FY 2019 Onwards (USD Billion)
Figure 7.5 Fresenius Kabi: Annual Revenues, FY 2019 Onwards (EUR Billion)
Figure 7.6 Lonza: Annual Revenues, FY 2019 Onwards (CHF Billion)
Figure 7.7 Thermo Fisher Scientific (Parent Company of Patheon pharma services): Annual Revenues, FY 2019 Onwards (USD Billion)
Figure 7.8 Recipharm: Annual Revenues, FY 2019 Onwards (EUR Million)
Figure 7.9 WACKER: Annual Revenues, FY 2019 Onwards (EUR Billion)
Figure 7.10 WuXi Biologics: Annual Revenues, FY 2019 Onwards (RMB Billion)
Figure 8.1 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers Based in North America
Figure 8.2 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Ampoules in North America
Figure 8.3 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Cartridges in North America
Figure 8.4 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Syringes in North America
Figure 8.5 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Vials in North America
Figure 8.6 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers Based in Europe
Figure 8.7 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Ampoules in Europe
Figure 8.8 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Cartridges in Europe
Figure 8.9 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Syringes in Europe
Figure 8.10 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Vials in Europe
Figure 8.11 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers Based in Asia-Pacific and Rest of the World
Figure 8.12 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Ampoules in Asia-Pacific and Rest of the World
Figure 8.13 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Cartridges in Asia-Pacific and Rest of the World
Figure 8.14 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Syringes in Asia-Pacific and Rest of the World
Figure 8.15 Company Competitiveness Analysis: Companies Offering Fill / Finish Services for Vials in Asia-Pacific and Rest of the World
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Service Offered
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Process Involved
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Biologic Involved
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: International and Local Agreements
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Expansions: Cumulative Year-wise Trend
Figure 10.2 Expansions: Distribution by Type of Expansion
Figure 10.3 Expansions: Distribution by Type of Primary Packaging Container Used
Figure 10.4 Expansions: Distribution by Type of Expansion and Type of Service Offered
Figure 10.5 Expansions: Distribution by Type of Biologic Involved
Figure 10.6 Expansions: Distribution by Type of Biologic Involved and Scale of Operation
Figure 10.7 Most Active Players: Distribution by Number of Expansions
Figure 10.8 Expansions: Distribution by Geography
Figure 10.9 Expansions: Distribution by Year of Expansion and Location of Expanded Facility
Figure 10.10 Expansions Undertaken in North America: Distribution by Type of Service Offered and Type of Biologic Involved
Figure 10.11 Expansions Undertaken in Europe: Distribution by Type of Service Offered and Type of Biologic Involved
Figure 10.12 Expansions Undertaken in Asia-Pacific and rest of the World: Distribution by Type of Service Offered and Type of Biologic Involved Figure 11.1 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Company Size
Figure 11.2 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Geography
Figure 11.3 Biologics Fill / Finish Capacity for Ampoules in North America
Figure 11.4 Biologics Fill / Finish Capacity for Ampoules in Europe
Figure 11.5 Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
Figure 11.6 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Company Size
Figure 11.7 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Geography
Figure 11.8 Biologics Fill / Finish Capacity for Cartridges in North America
Figure 11.9 Biologics Fill / Finish Capacity for Cartridges in Europe
Figure 11.10 Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
Figure 11.11 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Company Size
Figure 11.12 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Geography
Figure 11.13 Biologics Fill / Finish Capacity for Syringes in North America
Figure 11.14 Biologics Fill / Finish Capacity for Syringes in Europe
Figure 11.15 Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
Figure 11.16 Biologics Fill / Finish Capacity for Syringes in Rest of the World
Figure 11.17 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Company Size
Figure 11.18 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Geography
Figure 11.19 Biologics Fill / Finish Capacity for Vials in North America
Figure 11.20 Biologics Fill / Finish Capacity for Vials in Europe
Figure 11.21 Biologics Fill / Finish Capacity for Vials in Asia-Pacific
Figure 11.22 Biologics Fill / Finish Capacity for Vials in Rest of the World
Figure 12.1 Global Annual Demand for Biologics Fill / Finish Manufacturing, till 2035 (in million liters)
Figure 12.2 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Scale of Operation
Figure 12.3 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Type of Primary Packaging Container Used
Figure 12.4 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Geography
Figure 13.1 Biologics Manufacturing and Fill / Finish: Key Performance Indicators (KPIs)
Figure 13.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 13.3 Financial Indicators: Big Pharma Perspective
Figure 13.4 Financial Indicators: Contract Manufacturers Perspective
Figure 13.5 Process and Capability Indicators: Comparative Analysis of KPI of Big Pharma Companies
Figure 13.6 Process/ Capability-related Indicators: Big Pharma Perspective
Figure 13.7 Process/ Capability-related Indicators: Contract Manufacturers Perspective
Figure 13.8 Market Reputation Indicators: Comparative Analysis of KPI of Big Pharma Companies
Figure 13.9 Market Reputation Indicators: Big Pharma Perspective
Figure 13.10 Market Reputation Indicators: Contract Manufacturers Perspective
Figure 13.11 Other Important Performance Indicators: Contract Manufacturers Perspective
Figure 14.1 Regional Capability Analysis: Biologics Fill / Finish Manufacturing Capabilities in North America
Figure 14.2 Regional Capability Analysis: Biologics Fill / Finish Manufacturing Capabilities in Europe
Figure 14.3 Regional Capability Analysis: Biologics Fill / Finish Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 15.1 Key Considerations for Selecting a Robotic System Figure 15.2 Advantages of Robotic Systems in Fill / Finish Operations
Figure 16.1 Key Drivers of Ready-to-Use Platform
Figure 17.1 Biologics Fill / Finish Manufacturing: Market Drivers
Figure 17.2 Biologics Fill / Finish Manufacturing: Market Restraints
Figure 17.3 Biologics Fill / Finish Manufacturing: Market Opportunities
Figure 17.4 Biologics Fill / Finish Manufacturing: Market Challenges
Figure 18.1 Global Biologics Fill / Finish Manufacturing Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 18.2 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
Figure 18.3 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
Figure 19.1 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2018, 2024 and 2035
Figure 19.2 Biologics Fill / Finish Manufacturing Market for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 19.3 Biologics Fill / Finish Manufacturing Market for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 19.4 Biologics Fill / Finish Manufacturing Market for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 19.5 Biologics Fill / Finish Manufacturing Market for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.1 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2024 and 2035
Figure 20.2 Biologics Fill / Finish Manufacturing Market for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.3 Biologics Fill / Finish Manufacturing Market for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.4 Biologics Fill / Finish Manufacturing Market for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.5 Biologics Fill / Finish Manufacturing Market for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.6 Biologics Fill / Finish Manufacturing Market for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.7 Biologics Fill / Finish Manufacturing Market for Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 20.8 Biologics Fill / Finish Manufacturing Market for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 21.1 Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2018, 2024 and 2035
Figure 21.2 Biologics Fill / Finish Manufacturing Market for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 21.3 Biologics Fill / Finish Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 22.1 Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
Figure 22.2 Biologics Fill / Finish Manufacturing Market for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 22.3 Biologics Fill / Finish Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 22.4 Biologics Fill / Finish Manufacturing Market for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 22.5 Biologics Fill / Finish Manufacturing Market for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 22.6 Biologics Fill / Finish Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 22.7 Biologics Fill / Finish Manufacturing Market for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 23.1 Biologics Fill / Finish Manufacturing Market: Distribution by End-users, 2018, 2024 and 2035
Figure 23.2 Biologics Fill / Finish Manufacturing Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 23.3 Biologics Fill / Finish Manufacturing Market for Contract Manufacturing Organizations / Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 24.1 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player, 2018, 2024 and 2035
Figure 24.2 Biologics Fill / Finish Manufacturing Market for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 24.3 Biologics Fill / Finish Manufacturing Market for Non-Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.1 Biologics Fill / Finish Manufacturing Market: Distribution by Company Size, 2018, 2024 and 2035
Figure 25.2 Biologics Fill / Finish Manufacturing Market for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.3 Biologics Fill / Finish Manufacturing Market for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.4 Biologics Fill / Finish Manufacturing Market for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.1 Biologics Fill / Finish Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 26.2 Biologics Fill / Finish Manufacturing Market in North America, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.3 Biologics Fill / Finish Manufacturing Market in the US, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.4 Biologics Fill / Finish Manufacturing Market in Canada, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.5 Biologics Fill / Finish Manufacturing Market in Mexico, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.6 Biologics Fill / Finish Manufacturing Market in Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.7 Biologics Fill / Finish Manufacturing Market in France, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.8 Biologics Fill / Finish Manufacturing Market in Germany, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.9 Biologics Fill / Finish Manufacturing Market in the UK, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.10 Biologics Fill / Finish Manufacturing Market in Italy, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.11 Biologics Fill / Finish Manufacturing Market in Spain, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.12 Biologics Fill / Finish Manufacturing Market in Austria, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.13 Biologics Fill / Finish Manufacturing Market in Switzerland, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.14 Biologics Fill / Finish Manufacturing Market in Rest of Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.15 Biologics Fill / Finish Manufacturing Market in Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.16 Biologics Fill / Finish Manufacturing Market in China, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.17 Biologics Fill / Finish Manufacturing Market in India, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.18 Biologics Fill / Finish Manufacturing Market in South Korea, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.19 Biologics Fill / Finish Manufacturing Market in Japan, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.20 Biologics Fill / Finish Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.21 Biologics Fill / Finish Manufacturing Market in Rest of the World, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.22 Biologics Fill / Finish Manufacturing Market in Argentina, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.23 Biologics Fill / Finish Manufacturing Market in Brazil, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.24 Biologics Fill / Finish Manufacturing Market in Israel, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.25 Biologics Fill / Finish Manufacturing Market in Iran, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.26 Biologics Fill / Finish Manufacturing Market in Other Countries, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.1 Concluding Remarks: Overall Market Landscape
Figure 28.2 Concluding Remarks: Partnerships and Collaborations
Figure 28.3 Concluding Remarks: Recent Expansions
Figure 28.4 Concluding Remarks: Capacity Analysis
Figure 28.5 Concluding Remarks: Demand Analysis
Figure 28.6 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 28.7 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)

LIST OF TABLES

Table 5.1 Best-Selling Drugs (Based on revenue generated through the sales of the drug in FY 20XX)
Table 6.1 Biologics Fill / Finish Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters, Number and Location of Fill / Finish Facilities
Table 6.2 Biologics Fill / Finish Service Providers: Information on Scale of Operation and Type of Biologic Manufactured
Table 6.3 Biologics Fill / Finish Service Providers: Information on Type of Dosage Form and Type of Primary Packaging Container Used
Table 6.4 Biologics Fill / Finish Service Providers: Information on Additional Services Offered
Table 7.1 Biologics Fill / Finish Service Providers: List of Companies Profiled
Table 7.2 AbbVie Contract Manufacturing: Company Overview Table 7.3 AbbVie Contract Manufacturing: Biologics Fill / Finish Service Portfolio
Table 7.4 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 7.5 Asymchem: Company Overview Table 7.6 Asymchem: Biologics Fill / Finish Service Portfolio
Table 7.7 Asymchem: Recent Developments and Future Outlook
Table 7.8 Boehringer Ingelheim BioXcellence: Company Overview
Table 7.9 Boehringer Ingelheim BioXcellence: Biologics Fill / Finish Service Portfolio
Table 7.10 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 7.11 Catalent Biologics: Company Overview Table 7.12 Catalent Biologics: Biologics Fill / Finish Service Portfolio
Table 7.13 Catalent Biologics: Recent Developments and Future Outlook
Table 7.14 Fresenius Kabi: Company Overview
Table 7.15 Fresenius Kabi: Biologics Fill / Finish Service Portfolio
Table 7.16 Fresenius Kabi: Recent Developments and Future Outlook
Table 7.17 Lonza: Company Overview Table 7.18 Lonza: Biologics Fill / Finish Service Portfolio
Table 7.19 Lonza: Recent Developments and Future Outlook Table 7.20 Patheon pharma services: Company Overview
Table 7.21 Patheon pharma services: Biologics Fill / Finish Service Portfolio
Table 7.22 Patheon pharma services: Recent Developments and Future Outlook
Table 7.23 Recipharm: Company Overview Table 7.24 Recipharm: Biologics Fill / Finish Service Portfolio
Table 7.25 Recipharm: Recent Developments and Future Outlook
Table 7.26 WACKER: Company Overview
Table 7.27 WACKER: Biologics Fill / Finish Service Portfolio
Table 7.28 WACKER: Recent Developments and Future Outlook
Table 7.29 WuXi Biologics: Company Overview
Table 7.30 WuXi Biologics: Biologics Fill / Finish Service Portfolio
Table 7.31 WuXi Biologics: Recent Developments and Future Outlook
Table 7.32 Charles River: Company Overview
Table 7.33 Charles River: Biologics Fill / Finish Service Portfolio
Table 7.34 Element Materials Technology: Company Overview
Table 7.35 Element Materials Technology: Biologics Fill / Finish Service Portfolio
Table 7.36 Evonik: Company Overview Table 7.37 Evonik: Biologics Fill / Finish Service Portfolio
Table 7.38 Fareva: Company Overview Table 7.39 Fareva: Biologics Fill / Finish Service Portfolio
Table 7.40 GSK: Company Overview Table 7.41 GSK: Biologics Fill / Finish Service Portfolio
Table 7.42 Hetero: Company Overview Table 7.43 Hetero: Biologics Fill / Finish Service Portfolio
Table 7.44 Pierre Fabre: Company Overview Table 7.45 Pierre Fabre: Biologics Fill / Finish Service Portfolio
Table 7.46 Sandoz: Company Overview Table 7.47 Sandoz: Biologics Fill / Finish Service Portfolio
Table 7.48 Syngene: Company Overview Table 7.49 Syngene: Biologics Fill / Finish Service Portfolio
Table 9.1 Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations
Table 9.2 Partnerships and Collaborations: Information on Type of Service Offered and Type of Process Involved
Table 9.3 Partnerships and Collaborations: Information on Type of Biologic Involved
Table 10.1 Biologics Fill / Finish Service Providers: List of Recent Expansions
Table 10.2 Expansions: Information on Type of Primary Packaging Container Used
Table 10.3 Expansions: Information on Type of Service Offered
Table 10.4 Expansions: Information on Scale of Operation and Type of Biologic Involved
Table 11.1 Biologics Fill / Finish Service Providers: Information on Total Capacity for Ampoules (Sample Dataset)
Table 11.2 Biologics Fill / Finish Service Providers: Average Capacity for Ampoules by Company Size (Sample Dataset)
Table 11.3 Global Installed Biologics Fill / Finish Capacity for Ampoules: Total Capacity by Company Size (in terms of units)
Table 11.4 Biologics Fill / Finish Service Providers: Information on Total Capacity for Cartridges (Sample Dataset)
Table 11.5 Biologics Fill / Finish Service Providers: Average Capacity for Cartridges by Company Size (Sample Dataset)
Table 11.6 Global Installed Biologics Fill / Finish Capacity for Cartridges: Total Capacity by Company Size (in terms of units)
Table 11.7 Biologics Fill / Finish Service Providers: Information on Total Capacity for Syringes (Sample Dataset)
Table 11.8 Biologics Fill / Finish Service Providers: Average Capacity for Syringes by Company Size (Sample Dataset)
Table 11.9 Global Installed Biologics Fill / Finish Capacity for Syringes: Total Capacity by Company Size (in terms of units)
Table 11.10 Biologics Fill / Finish Service Providers: Information on Total Capacity for Vials (Sample Dataset)
Table 11.11 Biologics Fill / Finish Service Providers: Average Capacity for Vials by Company Size (Sample Dataset)
Table 11.12 Global Installed Biologics Fill / Finish Capacity for Vials: Total Capacity by Company Size (in terms of units)
Table 15.1 Biologics Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
Table 15.2 List of Pharmaceutical Robotics Manufacturers
Table 15.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Containers
Table 16.1 List of Companies Supplying Ready-to-Use Packaging Components
Table 27.1 IDT Biologika: Company Snapshot
Table 27.2 Alcami: Company Snapshot
Table 27.3 Cytovance Biologics: Company Snapshot
Table 27.4 Syngene: Company Snapshot
Table 27.5 oncomed manufacturing: Company Snapshot
Table 27.6 Eurofins BioPharma Product Testing Netherlands: Company Snapshot
Table 27.7 Yposkesi: Company Snapshot
Table 27.8 HALIX: Company Snapshot
Table 27.9 Mabion: Company Snapshot
Table 29.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Table 29.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Table 29.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 29.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 29.5 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Table 29.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Manufactured
Table 29.7 Biologics Fill / Finish Service Providers: Distribution by Type of Dosage Form
Table 29.8 Biologics Fill / Finish Service Providers: Distribution by Type of Primary Packaging Container Used
Table 29.9 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
Table 29.10 AbbVie (Parent Company of AbbVie Contract Manufacturing): Annual Revenues, FY 2019 Onwards (USD Billion)
Table 29.11 Asymchem: Annual Revenues, FY 2019 Onwards (RMB Billion)
Table 29.12 Boehringer Ingelheim (Parent Company of Boehringer Ingelheim BioXcellence): Annual Revenues, FY 2019 Onwards (EUR Billion)
Table 29.13 Catalent (Parent Company of Catalent Biologics): Annual Revenues, FY 2019 Onwards (USD Billion)
Table 29.14 Fresenius Kabi: Annual Revenues, FY 2019 Onwards (EUR Billion)
Table 29.15 Lonza: Annual Revenues, FY 2019 Onwards (CHF Billion)
Table 29.16 Thermo Fisher Scientific (Parent Company of Patheon pharma services): Annual Revenues, FY 2019 Onwards (USD Billion)
Table 29.17 Recipharm: Annual Revenues, FY 2019 Onwards (EUR Million)
Table 29.18 WACKER: Annual Revenues, FY 2019 Onwards (EUR Billion)
Table 29.19 WuXi Biologics: Annual Revenues, FY 2019 Onwards (RMB Billion)
Table 29.20 Partnerships and Collaborations: Cumulative Year-wise Trend
Table 29.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.22 Partnerships and Collaborations: Distribution by Scale of Operation
Table 29.23 Partnerships and Collaborations: Distribution by Type of Service Offered
Table 29.24 Partnerships and Collaborations: Distribution by Type of Process Involved
Table 29.25 Partnerships and Collaborations: Distribution by Type of biologic Involved
Table 29.26 Most Active Players: Distribution by Number of Partnerships
Table 29.27 Partnerships and Collaborations: International and Local Agreements
Table 29.28 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 29.29 Expansions: Cumulative Year-wise Trend Table 29.30 Expansions: Distribution by Type of Expansion
Table 29.31 Expansions: Distribution by Type of Primary Packaging Container Used
Table 29.32 Expansions: Distribution by Type of Expansion and Type of Service Offered
Table 29.33 Expansions: Distribution by Type of Biologic Involved
Table 29.34 Expansions: Distribution by Type of Biologic Involved and Scale of Operation
Table 29.35 Most Active Players: Distribution by Number of Expansions
Table 29.36 Expansions: Distribution by Geography Table 29.37 Expansions: Distribution by Year of Expansion and Location Expanded Facility
Table 29.38 Expansions Undertaken in North America: Distribution by Type of Service Offered and Type of Biologic Involved
Table 29.39 Expansions Undertaken in Europe: Distribution by Type of Service Offered and Type of Biologic Involved
Table 29.40 Expansions Undertaken in Asia-Pacific and rest of the World: Distribution by Type of Service Offered and Type of Biologic Involved
Table 29.41 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Company Size
Table 29.42 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Geography
Table 29.43 Biologics Fill / Finish Capacity for Ampoules in North America Table 29.44 Biologics Fill / Finish Capacity for Ampoules in Europe
Table 29.45 Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
Table 29.46 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Company Size
Table 29.47 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Geography
Table 29.48 Biologics Fill / Finish Capacity for Cartridges in North America
Table 29.49 Biologics Fill / Finish Capacity for Cartridges in Europe
Table 29.50 Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
Table 29.51 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Company Size
Table 29.52 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Geography
Table 29.53 Biologics Fill / Finish Capacity for Syringes in North America
Table 29.54 Biologics Fill / Finish Capacity for Syringes in Europe
Table 29.55 Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
Table 29.56 Biologics Fill / Finish Capacity for Syringes in Rest of the World
Table 29.57 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Company Size
Table 29.58 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Geography
Table 29.59 Biologics Fill / Finish Capacity for Vials in North America
Table 29.60 Biologics Fill / Finish Capacity for Vials in Europe
Table 29.61 Biologics Fill / Finish Capacity for Vials in Asia-Pacific
Table 29.62 Biologics Fill / Finish Capacity for Vials in Rest of the World
Table 29.63 Global Annual Demand for Biologics Fill / Finish Manufacturing, till 2035 (in million liters)
Table 29.64 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Scale of Operation (in million liters)
Table 29.65 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Type of Primary Packaging Container Used (in million liters)
Table 29.66 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Geography (in million liters)
Table 29.67 Global Biologics Fill / Finish Manufacturing Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.68 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
Table 29.69 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
Table 29.70 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2018, 2024 and 2035
Table 29.71 Biologics Fill / Finish Manufacturing Market for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.72 Biologics Fill / Finish Manufacturing Market for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.73 Biologics Fill / Finish Manufacturing Market for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.74 Biologics Fill / Finish Manufacturing Market for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.75 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2024 and 2035
Table 29.76 Biologics Fill / Finish Manufacturing Market for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.77 Biologics Fill / Finish Manufacturing Market for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.78 Biologics Fill / Finish Manufacturing Market for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.79 Biologics Fill / Finish Manufacturing Market for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.80 Biologics Fill / Finish Manufacturing Market for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.81 Biologics Fill / Finish Manufacturing Market for Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.82 Biologics Fill / Finish Manufacturing Market for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.83 Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2018, 2024 and 2035
Table 29.84 Biologics Fill / Finish Manufacturing Market for Commercial Scale of Operation, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.85 Biologics Fill / Finish Manufacturing Market for Preclinical / Clinical Scale of Operation, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.86 Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
Table 29.87 Biologics Fill / Finish Manufacturing Market for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.88 Biologics Fill / Finish Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.89 Biologics Fill / Finish Manufacturing Market for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.90 Biologics Fill / Finish Manufacturing Market for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.91 Biologics Fill / Finish Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.92 Biologics Fill / Finish Manufacturing Market for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.93 Biologics Fill / Finish Manufacturing Market: Distribution by End-users, 2018, 2024 and 2035
Table 29.94 Biologics Fill / Finish Manufacturing Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.95 Biologics Fill / Finish Manufacturing Market for Contract Manufacturing Organizations / Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.96 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player, 2018, 2024 and 2035
Table 29.97 Biologics Fill / Finish Manufacturing Market for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.98 Biologics Fill / Finish Manufacturing Market for Non-Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.99 Biologics Fill / Finish Manufacturing Market: Distribution by Company Size, 2018, 2024 and 2035

Table 29.100 Biologics Fill / Finish Manufacturing Market for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.101 Biologics Fill / Finish Manufacturing Market for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.102 Biologics Fill / Finish Manufacturing Market for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.103 Biologics Fill / Finish Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 29.104 Biologics Fill / Finish Manufacturing Market in North America, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.105 Biologics Fill / Finish Manufacturing Market in the US, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.106 Biologics Fill / Finish Manufacturing Market in Canada, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.107 Biologics Fill / Finish Manufacturing Market in Mexico, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.108 Biologics Fill / Finish Manufacturing Market in Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.109 Biologics Fill / Finish Manufacturing Market in France, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.110 Biologics Fill / Finish Manufacturing Market in Germany, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.111 Biologics Fill / Finish Manufacturing Market in the UK, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.112 Biologics Fill / Finish Manufacturing Market in Italy, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.113 Biologics Fill / Finish Manufacturing Market in Spain, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.114 Biologics Fill / Finish Manufacturing Market in Austria, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.115 Biologics Fill / Finish Manufacturing Market in Switzerland, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.116 Biologics Fill / Finish Manufacturing Market in Rest of Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.117 Biologics Fill / Finish Manufacturing Market in Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.118 Biologics Fill / Finish Manufacturing Market in China, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.119 Biologics Fill / Finish Manufacturing Market in India, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.120 Biologics Fill / Finish Manufacturing Market in South Korea, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.121. Biologics Fill / Finish Manufacturing Market in Japan, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.122 Biologics Fill / Finish Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.123 Biologics Fill / Finish Manufacturing Market in Rest of the World, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.124 Biologics Fill / Finish Manufacturing Market in Argentina, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.125 Biologics Fill / Finish Manufacturing Market in Brazil, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.126 Biologics Fill / Finish Manufacturing Market in Israel, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.127 Biologics Fill / Finish Manufacturing Market in Iran, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 29.128 Biologics Fill / Finish Manufacturing Market in Other Countries, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie Contract Manufacturing
Asymchem
Boehringer Ingelheim BioXcellence
Catalent Biologics
Charles River
Evonik
Fareva
Fresenius Kabi
GSK
Hetero
Lonza
Patheon Pharma Services
Pierre Fabre
Recipharm
Sandoz
Syngene
WACKER
WuXi Biologics

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4232EUR$4,799USD£3,651GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6173EUR$6,999USD£5,324GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€15874EUR$17,999USD£13,692GBP